AnaptysBio 的 rosnilimab 试验显示出减轻类风湿性关节炎症状、实现关键目标的前景。 AnaptysBio's rosnilimab trial shows promise in reducing rheumatoid arthritis symptoms, meeting key goals.

AnaptysBio第2b阶段对风湿性关节炎的rosnilimab试验取得了积极成果,实现了首要目标,并显示第12周的疾病活动计分(DAS-28)有显著改善。 AnaptysBio's Phase 2b trial of rosnilimab for rheumatoid arthritis showed positive results, meeting its primary goal and demonstrating significant improvement in the Disease Activity Score (DAS-28) at Week 12. 包括不同剂量的药物和安慰剂在内的试验发现,中值CRP水平减少了近50%,而且试验结果良好,没有产生重大不利影响。 The trial, which included different doses of the drug and a placebo, found a nearly 50% reduction in mean CRP levels and was well-tolerated with no significant adverse effects. AnaptysBio计划在2025年第二季度公布完整数据和其他调查结果。 AnaptysBio plans to release full data and additional findings in the second quarter of 2025.